Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
about
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Targeting the apoptosis pathway in hematologic malignanciesA small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.Distinct 5' UTRs regulate XIAP expression under normal growth conditions and during cellular stressSafety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsEvaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.IRES-mediated translation of cellular messenger RNA operates in eIF2α- independent manner during stress.XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.Expression of human papillomavirus-related proteins and its clinical implication in tonsillar squamous cell carcinoma.Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation.A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapyIAP proteins as targets for drug development in oncologyPhase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.Clinical pharmacokinetics of second generation antisense oligonucleotides.XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
P2860
Q26771601-EDD670EA-6C87-4E48-83DF-0A8E03C17AB9Q27024422-5A6064DD-9E7B-4AC5-B12D-3D0BF80E1929Q33620098-4DBA98EB-C5D9-4A9F-984C-5FD90F035BCAQ33809839-2A3A6586-F452-4596-B40A-00E3794D17C5Q34058389-70EBFD6D-B327-4B80-9BEB-606413C1D81BQ34206206-339ADD5A-7911-4EEA-82D1-912CC52C0E18Q35068026-E8B8E258-2B9C-43E3-A33A-29CC54416A69Q35653933-69FDDCFA-4B74-4389-B31F-7FBA3B7F4B27Q35672175-65E608AA-ED90-4A3E-864A-808610645038Q36034921-EF75EC30-5E25-4C8D-A19F-2634E44B591AQ36343628-04B105EA-6788-4029-A19A-C4E905A68A67Q36385291-BAF13908-0E7E-4331-92DD-102D0C0FE6EFQ36445265-1E0C1692-E058-492D-A3B1-03E75C564ABEQ36495236-71132BA9-3D7B-4A2B-8121-E877D84FCB06Q37209606-134F01D5-23E9-4558-B059-6806B5C4CF53Q37355664-AD54980F-14FA-4C01-9650-DDA0B58FCB88Q37602717-E7DCD5C5-C872-4591-BB64-002D3C91BD94Q37621564-3BEAFA52-7C5A-49E5-9129-E58BA3CFB86FQ37798159-D5094674-786F-4AE5-8231-4FBA6FDF2F73Q38066620-8EC2EC79-E3A8-4298-A10B-4E89AF053066Q38099047-2F1075F3-5651-43C1-8083-BFCD44711647Q40298219-1303B8A1-2242-45BA-8E86-191DD0C38C03Q42111132-1DFF757D-D055-4D66-B4D8-CAC98B0E6623Q42949488-78C7ECD1-22C3-4100-9E4E-9BE5F1991427Q51746852-D158BA32-1B80-4637-A1AA-9A6F317C2473
P2860
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@ast
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@en
type
label
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@ast
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@en
prefLabel
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@ast
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@en
P2093
P356
P1476
Phase I trial of AEG35156 admi ...... th advanced refractory cancer.
@en
P2093
Debra Jowle
Duncan Jodrell
Eric Lacasse
Gemma Dickinson
Jacques Jolivet
Jeff Cummings
Jon Durkin
Kate Connolly
Leon Aarons
Lesley Robson
P304
P356
10.1200/JCO.2008.19.5677
P407
P577
2009-02-23T00:00:00Z